MLC1501 Study Assessing Efficacy in STROke Recovery
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of
MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to
orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching
placebo for 24 weeks.